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Hereditary folate malabsorption is a rare autosomal recessive disorder caused by impaired 
active folate transport across membranes and into the central nervous system due to loss-
of-function mutations in proton-coupled folate transporter (PCFT). Newborns with this 
condition have initially normal folate stores, but as they are unable to absorb dietary folate 
and use rapidly their stores because of their growth demands, symptoms appear in the early 
infancy. Significant neurological morbidity usually follows the initial non-specific clinical 
presentation and delayed initiation of treatment. High dose oral and parenteral folinic acid 
treatment have been previously reported in literature to improve the clinical outcome 
without achieving optimal cerebrospinal fluid (CSF) folate levels though. The active isomer of 
5-formyltetrahydrofolate, also known as levofolinic acid, is available for administration. We 
report our experience in achieving normal (age dependent) CSF 5-Methyltetrahydrofolate (5-
MTHF) levels following daily intramuscular administration of levofolinic acid in three patients 
with HFM. Follow up assessment with repeated lumbar punctures has shown a stabilization 
of 5-MTHF levels within normal range. Clinical features and brain MRI findings had as well 
either improvement or stabilization. To the best of our knowledge, we provide as well for 




Hereditary folate malabsorption (HFM; OMIM 229050) is a rare autosomal recessive 
disorder caused by impaired active folate transport across membranes and into the central 
nervous system due to loss-of-function mutations in proton-coupled folate transporter 
(PCFT) [1-3]. The severe systemic folate deficiency concomitant with impaired transport of 
folate across the blood-choroid plexus-brain barrier represents the pathophysiological basis 
of the disease and results in a marked deficiency of cerebrospinal fluid (CSF) folate [3-5]. 
Infants with HFM come to medical attention in early infancy when they present with 
non-specific systemic findings such as failure to thrive, feeding difficulties, diarrhea, 
megaloblastic anaemia and/or pancytopenia [1, 6]. One the most unique aspects of the 
disease is an immune deficiency which occurs in a setting of significant 
hypogammaglobulinemia resulting in infections with unusual organisms [6, 7]. Neurologic 
symptoms may present concomitantly or develop progressively without adequate treatment 
[1, 6]. Developmental delay, peripheral neuropathy, movement disorder, behavioral issues 
and seizures have been observed in the vast majority of reported patients with HFM [1, 6]. 
Diagnosis is suspected on the basis of the above mentioned clinical features and 
haematological findings, which should prompt the clinician to measure CSF 5-
methyltetrahydrofolate (5-MTHF) levels which are usually very low or undetectable. 
Confirmation of the diagnosis is made by detection of biallelic disease causing mutations in 
the SLC46A1 gene. 
Early diagnosis is important for the initiation of treatment. Previous literature reports 
recommend high doses of oral or intramuscular (im) 5-formyltetrahydrofolate (5-formylTHF), 
also known as folinic acid, aiming to improve or normalize 5-MTHF CSF levels before 
irreversible damage occurs [1, 6]. Nevertheless, those levels are difficult to achieve even in 
patients who have been receiving high doses of parenteral folinic acid [8]. The active isomer 
of 5-formylTHF, also known as levofolinic acid, is as well available for administration. 
Anecdotal observations suggest that the active isomer might be more effective, especially in 
patients with neurological involvement and refractory seizures [1]. Herein we report 3 cases 
of patients with HFM who received im levofolinate treatment. Follow up assessment with 
repeated lumbar punctures has shown a normalization of their 5-MTHF levels and 
stabilization of clinical features and brain MRI findings. Based on achieving normal CSF 5-
MTHF results, to the best of our knowledge, we provide for the first time data in regards to 
the im levofolinate treatment dosage. 
 
Case presentation 1 
 
The first patient is the only son of non-consanguineous parents of British origin, born 
at term following an uneventful pregnancy. This patient’s clinical features were previously 
reported [9]. He presented to his local hospital at 2 months of age with failure to thrive, 
pallor, and diarrhea. He was diagnosed with Pneumocyctis jiroveci pneumonia. Initial work-
up showed megaloblastic anaemia, neutropenia, undetectable serum folate with normal 
vitamin B12 levels. IgG levels were normal but IgA and IgM levels were low. Following initial 
intravenous folinic acid replacement patient was discharged home on oral folic acid 
supplementation of 1.5 mg/day and immunoglobulin replacement therapy. 
Follow-up at 6 months of age demonstrated macrocytic anemia, neutropenia, low 
serum/red cell folate and no specific immunodeficiency abnormalities. The dose of oral folic 
acid was increased. At the age of 13 months the patient showed developmental arrest, 
movement disorder and signs of central motor neuron involvement. The oral folic acid 
supplementation was again increased. At this point patient had a normal brain MRI and a 
lumbar puncture was unsuccessful. Even on high doses of oral folic acid patient continued to 
have the same clinical features and hematologic abnormalities. Based on the above 
constellation of findings HFM was suspected. Undetectable CSF 5-MTHF levels were in 
agreement with the clinical diagnosis (Table 1). Genetic analysis confirmed the diagnosis and 
patient was found to be compound heterozygous, with a mutant allele from his mother 
(c.204-205delCC) in exon 1 resulting in a frameshift starting at position N68 with early 
termination of translation, and a mutant allele from his father located in exon 2 (c.1004 C>A) 
resulting in an A335D loss-of-function point mutation [9]. At this point patient was started 
on im folinic acid which led to an improvement of his clinical features; nevertheless, CSF 5-
MTHF levels remained suboptimal. 
Annual reviews showed delay of gross/fine motor skills, significant visual perceptual 
difficulty as well as slow witnessed continuous acquisition of skills with support. At the age 
of 5½ years the patient developed sudden mood swings, drop attacks with occasional 
generalized tonic-clonic seizures. EEG confirmed complex partial seizures. Patient was 
started on antiepileptic treatment and im levofolinic acid was introduced. Results from a 
repeat lumbar puncture one year following the initiation of levofolinate have shown normal 
levels of 5-MTHF and brain MRI. Currently, at the age of 10 years the patient continues to 
have normal 5-MTHF CSF level and shows continuous developmental progress. To date, no 
local or systemic complications had been raised from the use of im injections.  
 
 
Table 1. Biochemical and neuroimaging findings in Patient 1 
 
Age CSF 5-MTHF Medication Imaging 
17months <1nmol/l 
ref. 72-305 
Folinic acid, 5mg/day, im 
(0.4mg/kg/d) 






Folinic acid, 12mg/day, im 
(0.8mg/kg/d) 
Non-specific myelination delay 
and lack of white matter bulk 
3years 31nmol/l  
(trough level) 
ref. 72-305 
Folinic acid, 12mg/day, im 
(0.71mg/kg/d) 
Subcortical white matter of 
bilateral cerebral hemispheres 
better myelinated, unchanged 
lack of white matter bulk, no 




Folinic acid, 12mg/day, im 
(0.6mg/kg/d) 
No abnormality demonstrated 
  






Normal intracranial and intra-
spinal appearances 
  

















Case presentation 2 
 
Patient 2 is the first male child of non consanguineous parents of Pakistani origin 
born at term after an uncomplicated pregnancy. He presented at 2 months of age with 
failure to thrive and irritability. On clinical examination patient presented subtle facial 
dysmorphism and hypospadias. Initial laboratory work-up showed severe pancytopenia 
requiring red blood cell and platelet transfusion. Plasma folate level was virtually zero and 
vitamin B12 was low. IM vitamin B12 and oral folic acid supplementation was started. Good 
progress was initially documented although plasma folate levels remained suboptimal and 
total plasma homocysteine was elevated. Vitamin B12 level normalized with im treatment 
within two months, however the patient was lost to follow up.  
Six months later, while in Pakistan, patient underwent brain CT scan, following new 
onset epilepsy. The scan demonstrated basal ganglia calcification and cerebral atrophy. At 
the age of 17 months the patient was admitted to PICU because of status epilepticus. Clinical 
examination revealed truncal hypotonia, movement disorder, and dystonia with poor visual 
interaction. EEG at that point showed hypsarrythymia. Because of the above constellation of 
findings a lumbar puncture for a full CSF work-up was done. The CSF 5-MTHF was 
undetectable with the rest of findings within normal range. Gene mutation analysis 
confirmed the diagnosis of hereditary folate malabsorption due to a homozygous c.198C>A, 
p.Cys66* mutation causing a premature stop codon. This mutation has been previously 
reported in literature in a patient who was compound heterozygous [10], but not in a 
homozygous state. Patient was started initially on oral folinic acid supplementation and 4 
months later on im daily injections which led to clinical and biochemical improvement. 
(Table 2). 
Although on im folinic acid therapy, patient’s neurologic progress was turbulent with 
recurrent PICU admissions for status epilepticus, development of infantile spasms and 
subsequently myoclonic jerks which required combined antiepileptic drugs. At the age of 2 
years the patient was started on im levofolinate treatment which led to the normalization of 
his 5-MTHF levels. Currently, at the age of 5 years the patient continues to have significant 
neurological deficit and intractable seizures, auditory and visual impairment and medication 
controlled movement disorder. 
 
Table 2. Biochemical and neuroimaging findings in Patient 2 
 
Age CSF 5-MTHF Medication Imaging 
17months <1 nmol/L  
ref. 72-305 
Folinic acid, 10mg/day, oral   
19months  <10 nmol/L  
(peak sample) 
ref. 72-305 








Ponto-cerebellar hypoplasia in 
addition to generalised lack of 
cerebral volume and myelination, 
bilateral symmetrical mature 
haemorrhagic infarction of the 
basal ganglia, symmetrical 
periventricular and deep white 
matter change over the frontal 


























No progression of 
prominent white matter 
changes and ponto- 
cerebellar volume reduction 
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Figure1. MRI brain T1 weighted image showing basal ganglia calcifications (A), ponto-
cerebellar hypoplasia (B) T2 weighted image (C) showing white matter changes over the 
frontal lobes. 
 
Case presentation 3 
 
Patient 3 is the younger brother of Patient 2. Parents have declined antenatal testing. The 
pregnancy was uneventful and patient was delivered at term in good condition. 
The investigations which were carried out on the second day of life showed mild 
thrombocytopenia, with normal serum folate red cell folate and homocysteine. CSF 5-MTHF 
level was nevertheless really low and levofolinate treatment was started at a dose of 
5mg/kg/day as one intramuscular daily dose (Table 3). Genetic analysis confirmed the 
presence of the same mutation as in the case of his brother in homozygous state. The 
neurologic progress and the brain MRI findings are normal up to date.  
 
Table 3. Biochemical and neuroimaging findings in Patient 3 
 
 
Age CSF 5-MTHF Medication Imaging 












Brain MRI –normal 










HFM is a rare autosomal recessive condition affecting folate metabolism. So far 37 
families have been described worldwide, out of which 30 have as well genetic confirmation 
[4, 6, 11-13]. Our patients were found to have mutations already described in literature as 
pathogenic [9, 10]. HFM is a multisystemic disease, which emphasizes the major role of 
folate in different tissues and organs. Patients ‘clinical features have been recently 
summarized [14]. Findings include poor feeding, faltering growth, megaloblastic anemia or 
even pancytopenia, diarrhea, immune dysfunction and neurological manifestations with 
progressive deterioration [1, 14, 15]. In our small cohort, Patient 1 and 2 had typical features 
of the disease, which in combination with the low 5-MTHF led to the diagnosis of HFM. The 
abnormal findings on brain MRI of Patient 2 included calcification of the basal ganglia. 
Intracranial calcifications have been reported in other patients with HFM, typically present in 
the cortex or basal ganglia [5, 16, 17]. 
There have been no formal studies assessing the different folate formulations, dosing 
and routes of administration that provide an evidence based regimen for optimal treatment. 
Most publications agree that parenteral administration of folinic acid is the only effective 
treatment for HFM. Even though anemia, immune dysfunction and gastrointestinal 
symptoms are reversible with the oral or parenteral administration of folinic acid and 
normalization of blood folate levels is easily achieved, it has been proven that CSF levels 
remain suboptimal [6, 7, 8, 10, 14, 15, 17]. Thus, the major challenge remains to achieve 
normal CSF 5-MTHF levels for treatment of neurological disease[6]. 
This paper presents for the first time evidence of the effective correction of CSF 5-
MTHF levels using im levofolinate in three patients with HFM. Two out of three patients 
were treated initially with oral and/or parenteral folinic acid, the racemic stable form of 
folate, which led to correction of the systemic manifestations. Nevertheless, CSF folate levels 
remained unsatisfactory, below the age dependant values, which prompted us to use 
levofolinate, the pharmacologically active isomer of 5-formylTHF. Daily im administration of 
the medication led to the normalization of 5-MTHF levels in the CSF and those levels remain 
stable and within normal range so far. Clinical features and brain MRI findings had as well 
either improvement or stabilization. Initial dose in each patient was decided based on trough 
CSF 5-MTHF levels, and previous dose of folinic acid in combination with current knowledge 
that the biologic impact of the active isomer is twice that of the racemic compound at the 
same dose [1].  
Finally, this paper describes the youngest patient diagnosed with HFM and treated on 
the second day of life. This patient had only mild thrombocytopenia without any additional 
systemic or neurological findings.  
Our patients did not experience any local or systemic complications as a 
consequence of the im injections. However, lifelong daily im administration is challenging 
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